Antiangiogenic Cancer Therapy

Name: Antiangiogenic Cancer Therapy
Brand: CRC Press

CRC Press

Antiangiogenic Cancer TherapyAuthor(s): Darren W. Davis, Roy S. Herbst, James L. Abbruzzese\nFormat: Paperback\nPublisher: Taylor & Francis Ltd, United Kingdom\nImprint: CRC Press\nISBN-13: 9780367388812, 978-0367388812\nSynopsis\nTop Investigators Explore the Complexities of Angiogenesis Cancer Research\n\nThe targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors. \n\nCompiles the results of four decades of progress \n\nIntegrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idei